BNP Paribas Financial Markets’s SpyGlass Pharma SGP Stock Holding History

BNP Paribas Financial Markets’s Portfolio SGP Stock Details SGP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$44.9K	Buy	+2,016	New	+$43.7K	﹤0.01%	4932

Other funds holding SGP

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

BNP Paribas Financial Markets's SGP Position: Q2 2026 in Review

BNP Paribas Financial Markets opened a new position in SpyGlass Pharma (SGP) in Q2 2026: 2,016 shares worth $44.9K. The stake represents ﹤0.01% of the portfolio and ranks #4932 among its holdings.

43 funds tracked by Wall St. Rank hold SGP as of Q2 2026.

BNP Paribas Financial Markets held 2,016 shares of SpyGlass Pharma worth $44.9K as of Q2 2026.
SpyGlass Pharma was a new BNP Paribas Financial Markets position in Q2 2026.
SpyGlass Pharma made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #4932 holding.
43 funds tracked by Wall St. Rank held SpyGlass Pharma as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.